ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of REGENXBIO, Inc. securities during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and the efficacy of its product candidate RGX-111 [1][5]. Group 1: Class Action Details - The class action lawsuit is on behalf of investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by April 14, 2026, to represent other class members in the litigation [1][3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been ranked highly for its performance in securities class action settlements [4]. Group 3: Case Specifics - The lawsuit alleges that REGENXBIO provided misleading information regarding its gene therapy product RGX-111, which is intended for treating severe Mucopolysaccharidosis Type I [5]. - Defendants reportedly made positive assertions about RGX-111's trial success while concealing adverse facts about its efficacy and safety [5].